



ASX Release

Adherium Investor Webinar Invitation

Melbourne, Australia – 18 February 2026: [Adherium Limited](#) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® platform is pleased to invite shareholders and prospective investors to an online investor briefing.

During the webinar, Adherium CEO, Dawn Bitz will discuss commercial momentum the Company is driving through its remote patient monitoring channel and its strategy to expand into value-based care contracts with US insurers. The presentation will also cover the equity raising launched on 16 February 2026, including both a placement and accelerated non-renounceable entitlement offer. The presentation will be followed by a Q+A session.

Register now:

Webinar date: Thursday 19 February 2026
Webinar time: 11.00am AEDT (Sydney/Melbourne)
Registration link: [Click here to register](#)

Once the registration form is completed, participants will receive a confirmation email with details on how to access the briefing.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
H^CK Director
haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com